

US drugmaker Mylan posts Q1 loss

US drugmaker Mylan reported a loss for the first quarter as revenues decreased by 7%. Adjusted earnings per share topped analysts' expectations, while quarterly revenues missed their estimates. Looking forward to the full year 2019, Mylan still expects adjusted earnings of USD 3.80 to USD 4.80 per share and revenues of USD 11.50 billion to USD 12.50 billion.